<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702920</url>
  </required_header>
  <id_info>
    <org_study_id>IG1407</org_study_id>
    <nct_id>NCT03702920</nct_id>
  </id_info>
  <brief_title>Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%</brief_title>
  <acronym>APACHE</acronym>
  <official_title>Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With &quot;Acute-On-Chronic Liver Failure&quot; (ACLF) at High Risk of Hospital Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to
      evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in
      acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study
      centers in the United States, Canada, and Europe with expertise in the management of subjects
      with ACLF.

      Subjects with ACLF at a high risk of hospital mortality will be enrolled. The study will
      consist of a Screening Period during which subjects will be randomized (1:1) to receive
      either standard medical treatment (SMT) + PE-A 5% (treatment group) or SMT only (control
      group), followed by a Treatment Period, and a Follow-up Period.

      The Treatment Period for subjects in the SMT+ PE-A 5% treatment group will be between 7 and
      17 days, depending on ACLF evolution.

      The Treatment Period for subjects in the SMT control group will be a minimum of 7 days for
      all subjects and up to 17 days depending on the ACLF evolution. Subjects in this group will
      receive SMT according to the institution's standards.

      The Follow-up Period for subjects in both groups will be 90 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 380 subjects with cirrhosis, ACLF, and high risk of hospital mortality
      (ACLF-1b, ACLF-2, or ACLF-3a) will be included in this study after obtaining written informed
      consent. In case of hepatic encephalopathy (HE), written informed consent will be obtained
      from a relative or a legally authorized representative (surrogate).

      Randomization of subjects will be stratified by region (European Union [EU] or North America
      [NA]) and the 3 ACLF grades (ACLF-1b, ACLF-2, or ACLF-3a). Within each stratum (ie, each
      unique combination of region and ACLF grade), subjects will be randomized in a 1:1 ratio into
      2 treatment groups below:

        -  SMT+PE-A 5% (treatment group)

        -  SMT (control group)

      SMT + PE-A 5% Treatment Group:

      PE-A 5% will be performed using 5% albumin (Albutein® 5%) as the main replacement fluid
      administered intravenously. Fresh frozen plasma (FFP) will be given after each PE-A 5%
      session to prevent coagulopathy.

      The exact number of sessions will be determined by the pattern of response (achieving
      complete response or no improvement/deterioration of ACLF) to PE-A 5% therapy. IVIGs will be
      administered to prevent the development of hypogammaglobulinemia and infection.

      SMT Control Group:

      The Treatment Period will be 7 days for all subjects and will be prolonged depending on
      subject's ACLF evolution to up to 17 days.

      Subjects in both the SMT+ PE-A 5% treatment group and the SMT control group will be followed
      for 90 days after randomization. During the entire study, the safety of both groups will be
      monitored by a Data Safety Monitoring Board.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death through Day 90</measure>
    <time_frame>Day 1 to Day 90</time_frame>
    <description>Time to death through Day 90 after randomization of SMT+PE-A 5% versus SMT alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to transplant or death through Day 90</measure>
    <time_frame>Day 1 to Day 90</time_frame>
    <description>Time to transplant or death through Day 90 after randomization of SMT+PE-A 5% versus SMT alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death through Day 28</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Time to death through Day 28 after randomization of SMT+PE-A 5% versus SMT alone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>SMT+ PE-A 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment (SMT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard medical treatment (SMT) will be administered according to institution standards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SMT + PE-A 5%</intervention_name>
    <description>Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.</description>
    <arm_group_label>SMT+ PE-A 5%</arm_group_label>
    <other_name>Albutein 5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>Standard medical treatment according to the institution's standard practice</description>
    <arm_group_label>Standard Medical Treatment (SMT)</arm_group_label>
    <other_name>SMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject must meet all the following inclusion criteria to be eligible for
             participation in this study:

               1. Male or female cirrhotic subjects between 18 and 79 years of age.

               2. Subjects with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during
                  hospitalization (must be ACLF-1b, -2, or -3a within the Screening Period [a
                  maximum of 10 days]).

               3. Willing and able to provide written informed consent or have an authorized
                  representative able to provide written informed consent on behalf of the subject
                  in accordance with local law and institutional policy.

               4. In case of HE, informed consent will be provided by a relative or a legally
                  authorized representative (surrogate).

        Exclusion Criteria:

          -  A subject meeting any of the following exclusion criteria is NOT eligible for
             participation in the study:

               1. Subjects without ACLF.

               2. Subjects with ACLF-1a or ACLF-3b after the Screening Period.

               3. Subjects fulfilling inclusion criteria that improve to no ACLF or to ACLF-1a or
                  worsen to ACLF-3b during the Screening Period (between initial evaluation and
                  time of randomization).

               4. Subjects with ACLF for more than 10 days prior to randomization.

               5. Subjects with acute or subacute liver failure without underlying cirrhosis.

               6. Subjects with septic shock lasting &gt;1 hour that does not respond to fluid
                  resuscitation-IV therapy or pharmacologic-pressors.

               7. Subjects with active bacterial or fungal infection with hemodynamic instability.

               8. Subjects with acute respiratory distress syndrome (ARDS) with peripheral oxygen
                  saturation (SpO^2) ≤89.

               9. Subjects with active or recent bleeding (unless controlled for &gt;48 hours).

              10. Subjects with severe thrombocytopenia (≤20×10^9/L) (based on local laboratory
                  assessment).

              11. Subjects with chronic renal failure and currently receiving hemodialysis.

              12. Evidence of current locally advanced or metastatic malignancy. Subjects with
                  hepatocellular carcinoma within the Milan criteria (1 nodule ≤5 cm or 3 nodules
                  ≤3 cm), non-melanocytic skin cancer, and controlled breast or prostate cancer,
                  can be included).

              13. Subjects with severe chronic heart failure (New York Heart Association class III
                  or IV).

              14. Subjects with severe pulmonary disease (Global Obstructive Lung Disease stage III
                  or IV).

              15. Subjects with severe myopathy as defined clinically.

              16. Subjects with a known infection with human immunodeficiency virus (HIV) or have
                  clinical signs and symptoms consistent with current HIV infection.

              17. Females who are pregnant, breastfeeding, or if of childbearing potential,
                  unwilling to practice a highly effective method of contraception (oral,
                  injectable, or implanted hormonal methods of contraception, placement of an
                  intrauterine device or intrauterine system, condom, or occlusive cap with
                  spermicidal foam/gel/cream/suppository, male sterilization, or true abstinence*)
                  throughout the study.

                    -  True abstinence: When this is in line with the preferred and usual lifestyle
                       of the subject. (Periodic abstinence [eg, calendar, ovulation,
                       symptothermal, post-ovulation methods], declaration of abstinence for the
                       duration of a trial, and withdrawal are not acceptable methods of
                       contraception).

              18. Subjects with previous liver transplantation.

              19. Subjects receiving anti-platelet or anti-coagulant therapy.

              20. Participation in another clinical study within at least 30 days prior to
                  screening.

              21. Subjects with active drug addiction.

              22. Subjects with a do-not-resuscitate order.

              23. In the opinion of the investigator, the subject may have compliance problems with
                  the protocol and the procedures of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ed Corsi</last_name>
    <phone>919-316-6222</phone>
    <email>approach_apache@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mireia Torres</last_name>
    <phone>+34 93 5710500</phone>
    <email>approach_apache@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo E. Vargas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ram Subramanian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jody Olson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers-New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Pyrsopoulos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Simonetto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Hanje, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Rajender Reddy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Al- Khafaji</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmohan Bajaj</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care, Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kramer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Reiberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université libre de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Gustot</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Wilmer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fin Stolze Larsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhael Giabicani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hépato-Biliaire - Hôpital Universitaire Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faouzi Saliba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Jansen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonel Trebicka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Maasoumy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Berg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Gerbes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Fagiuoli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Belli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Angeli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Cortez Pinto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Rua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario del Valle Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Vargas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Fernández</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Bañares</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustin Albillos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Bernal</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

